You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
DEVELOPMENT OF ENHANCEMENT TO DATA COLLECTION CAPABILITIES OF KWAJALEIN MISSILE RANGE SYSTEMS
SBC: SIGMATECH INC Topic: N/ATHE DATA COLLECTION FOR THE MILLIMETER WAVELENGTH INSTRUMENTATION RADAR, BASED ON THE KWAJALEIN ATOLL, COULD BE SIGNIFICANTLY ENHANCED IF THE RADAR IS MODIFIED TO PROVIDE A LIMITED FIELD OF VIEW (LFOV) CAPABILITY. THIS WOULD ALLOW THE RADAR TO HAVE THE SAME CAPABILITY AS A FULL PHASED ARRAY OVER A LIMITED ANGLE COVERAGE WHICH WOULD MEAN MORE THAN ONE TARGET COULD BE TRACKED AT A TIME. THE APPROACH ...
SBIR Phase I 1991 Department of DefenseArmy -
ADVANCED HYBRID MULTIPLE OBJECT RECOGNITION SYSTEM FOR A LASER RADAR IMAGE
SBC: SIGMATECH INC Topic: N/AN/A
SBIR Phase I 1992 National Aeronautics and Space Administration -
ALGORITHM DEVELOPMENT
SBC: SIGMATECH INC Topic: N/AN/A
SBIR Phase I 1988 Department of DefenseArmy -
A novel targeted therapy
SBC: BCN Biosciences L.L.C. Topic: NCIDESCRIPTION (provided by applicant): Cancer is the leading cause of mortality in the United States, despite many advances in the current therapies including surgery, radiation and chemotherapy. Therefore, it is imperative that novel targets for cancer therapeutic development are identified and explored in order to improve the outcome of this lethal disease. We recently exclusively licensed a novel ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
Translational research in a novel anti cancer agent
SBC: BCN Biosciences L.L.C. Topic: N/ADESCRIPTION (provided by applicant): Natural products possess the richest source of molecular diversity in existence. In the case of cancer therapeutics, natural products have yielded a significant number of novel and effective cancer treatment and prevent ive agents. As a commercial venture, BCN Biosciences has a commitment to identifying new chemical structures from plants and fungi, and the dev ...
SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
Botanical-derived drug discovery for cancer therapy
SBC: BCN Biosciences L.L.C. Topic: N/ADESCRIPTION (provided by applicant): In a screen for naturally occurring angiogenic inhibitors, we have identified an extract from the plant Livistona chinensis, which has potent anti-angiogenic and anti-tumor activity and is non-toxic in mice. To our know ledge, ours is the first publication in the English literature on this extract from Livistona chinensis. We hypothesize that the Livistona extr ...
SBIR Phase I 2008 Department of Health and Human ServicesNational Institutes of Health -
A dual acting drug for enhancing radiotherapeutic benefit
SBC: BCN Biosciences L.L.C. Topic: NCIABSTRACT: This proposal entitled A dual acting drug for enhancing radiotherapeutic benefit is designed to provide proof of concept evidence that the novel compound EWA001 can protect normal lung tissue from radiation-induced damage within an in vivo model without appreciably protecting neoplastic tissue. The protection of radiation induced lung toxicity from ionizing radiation and in particular ...
SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
The objective of this contract is to develop chemically modified mimics of microRNAs with improved activity and stability for the treatment of many diseases
SBC: MiRecule, Inc Topic: NIAIDApproximatelymillion people are currently living with human immunodeficiency virusHIVinfection worldwideWith no curative therapy on the horizonpatients must be on antiretroviral therapyARTfor decades to manage their diseaseBecause ART targets only actively replicating virustreatment interruption or ART failure leads to rebound of latent virusRNA therapeutics have shown great promise as a new mecha ...
SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Compact, cost-effective, and operator-friendly fundus camera for early detection
SBC: LUMETRICS INC Topic: NEIDESCRIPTION (provided by applicant): In order to reduce rates of preventable blindness, screening for treatable eye diseases has become increasingly important as the population ages in the United States and around the world. Early detection and diagnosis is vital to preserve retinal and optic nerve function. Currently, routine eye examinations are performed by highly skilled practitioners usi ...
SBIR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health -
SBIR Phase I: Fast Two-Color Heterodyne Non-Contact Scanning System for Mapping Optical Parameters of Human Eye
SBC: LUMETRICS INC Topic: EOThis Small Business Innovation Research Phase I project develops a high speed and high sensitivity system for measuring optical dimensions of human eye, such as the total axial length, corneal thickness and the location and thickness of the crystalline lens, in a non-contact manner using infrared light, invisible to the eye. This task is accomplished by improving the existing technique of time dom ...
SBIR Phase I 2008 National Science Foundation